How We're Changing the Story
Vida Pharmacal's story began in 2007 with Max, a Texas shelter dog. Max's inexplicable spiral into acute arrhythmia and death revealed the reality of vulnerable, overlooked humans and canines that suffer from Chagas disease. Today, our proprietary, patented therapeutic is pending approval as an effective, first-to-market treatment. Our novel lateral flow diagnostic assay enables in-clinic screening and early identification of infected patients. Our development pipeline is promising. Thanks to Max, we're now changing the story for thousands of canine—and hopefully soon, human—patients.
|
 |